Amerikanische Gesellschaft für Hirudotherapie

Assessment of leech therapy for knee osteoarthritis: a randomized study

Andereya S, Stanzel S, Maus U, Mueller-Rath R, Mumme T, Siebert CH, Stock F, Schneider U (2008) · Acta Orthopaedica · n=113

RCT evidence detailTrial reference
Sample size of this trial compared with other Knee Osteoarthritis trialsWang H 2018264Lauche R 2025240Lauche R 2014237Farzali S 2025181Cui Y 2024144Andereya S 2008113Andereya S 2008113Sarbaev IS 201996Isik M 201790Khoshnevisan A 202280
This trial (highlighted) by sample size alongside other indexed Knee Osteoarthritis trials. Larger trials generally carry more statistical weight.

Study Profile

Design
single-center, three-arm randomized study with patient blinding via 'artificial leech' simulated control (Aachen University Hospital)
Sample size (n)
113
Intervention
Single application of leeches (group I, n=38) or double application 4 weeks apart (group II, n=35); Hirudo medicinalis periarticularly at the symptomatic knee
Comparator
Control group (n=40) treated with an 'artificial leech' simulation device, with treatment blinded as far as feasible
Primary endpoint
KOOS and WOMAC scores plus VAS pain, monitored over 26 weeks with intake of pain medication tracked
Primary result
All three groups showed improvement in KOOS, WOMAC, and VAS pain after intervention; improvements were statistically significant for treatment groups I and II throughout the 26-week follow-up; greatest improvement seen in the double-treatment group with long-term reduction of joint stiffness and improved activities of daily living
Follow-up duration
26 weeks

Key Findings

  • First leech-OA RCT to include patient blinding via an 'artificial leech' simulated control arm
  • Three-arm design (single application n=38, double application n=35, artificial-leech control n=40) tested both dose-response and blinding
  • Repeated leech treatment (group II) produced the greatest long-term improvement in joint stiffness and activities of daily living
  • Authors explicitly acknowledged that the positive outcomes could reflect active substances, placebo effect, or expectation effects — methodologically honest about residual uncertainty
  • Reduction in pain medication intake statistically significant for both leech treatment arms over 26 weeks

Limitations

  • Sham control fidelity uncertain — 'artificial leech' design may not have fully blinded patients to allocation
  • Single center (Aachen) — same investigators as 2006 pilot and 2008 hyaluronic-acid trial, raising investigator-site dependence concerns
  • Authors explicitly note inability to distinguish biological from expectancy effects
  • 26-week follow-up still leaves long-term durability beyond 6 months unanswered
  • Three-arm allocation reduced per-arm power versus a two-arm superiority design

Clinical Implications

Andereya 2008 (Acta Orthopaedica) is methodologically the strongest of the early German leech-OA RCTs because it included an 'artificial leech' control intended to address the blinding limitation of Michalsen 2003 and the Aachen 2008 HA comparison. The trial confirms a robust effect of repeated leech therapy on KOOS, WOMAC and VAS pain in moderate-to-advanced knee OA at 26 weeks, while honestly acknowledging that the trial cannot fully separate biological from placebo effects. The result motivated the subsequent Hohmann 2014 plantar-fasciitis sham trial and the ongoing ELECT trial which uses a fully validated sham device. Clinicians should cite Andereya 2008 (Acta Orthopaedica) when discussing the question of whether the leech-OA effect persists under blinded conditions — the answer suggested here is yes, but with the methodological caveat that perfect blinding remains aspirational.

Related Trials

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.